Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

被引：4

作者：

Garcia-Manero, Guillermo ^{[1
]}

Platzbecker, Uwe ^{[2
]}

Santini, Valeria ^{[3
]}

Zeidan, Amer M. ^{[4
,5
]}

Fenaux, Pierre ^{[6
]}

Komrokji, Rami S. ^{[7
]}

Shortt, Jake ^{[8
,9
]}

Valcarcel, David ^{[10
]}

Jonasova, Anna ^{[11
]}

Dimicoli-Salazar, Sophie ^{[12
]}

Tiong, Ing Soo ^{[13
]}

Lin, Chien-Chin ^{[14
]}

Li, Jiahui ^{[15
]}

Zhang, Jennie ^{[15
]}

Giuseppi, Ana Carolina ^{[15
]}

Kreitz, Sandra ^{[16
]}

Pozharskaya, Veronika ^{[15
]}

Keeperman, Karen L. ^{[15
]}

Rose, Shelonitda ^{[15
]}

Prebet, Thomas ^{[15
]}

Degulys, Andrius ^{[17
,18
]}

Paolini, Stefania ^{[19
]}

Cluzeau, Thomas ^{[20
]}

Della Porta, Matteo Giovanni ^{[21
,22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Leipzig, Med Ctr, Dept Hematol Cellular Therapy Hemostaseol & Infec, Leipzig, Germany

[3] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, DMSC, Florence, Italy

[4] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA

[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[6] Univ Paris 07, Hop St Louis, Paris, France

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[8] Monash Univ, Melbourne, Australia

[9] Monash Hlth, Melbourne, Australia

[10] Hosp Univ Vall dHebron, Barcelona, Spain

[11] Charles Univ Prague, Gen Univ Hosp, Med Dept Hematol, Prague, Czech Republic

[12] Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France

[13] The Alfred, Malignant Haematol & Stem Cell Transplantat, Melbourne, Australia

[14] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Bristol Myers Squibb, Celgene Int Sarl, Boudry, Switzerland

[17] Vilnius Univ Hosp, Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania

[18] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania

[19] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[20] Univ Cote Azur, Dept Hematol Clin, CHU Nice, Nice, France

[21] Canc Ctr IRCCS Humanitas Res Hosp, Milan, Italy

[22] Humanitas Univ, Dept Biomed Sci, Milan, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 48 条

[1] Efficacy and safety of luspatercept versus epoetin alfa (EA) in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS): full analysis of the COMMANDS trial
Platzbecker, Uwe
Garcia-Manero, Guillermo
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Porta, Matteo Giovanni
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 243
[2] Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer Methqal
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Kreitz, Sandra
Pozharskaya, Veronika
Shetty, Jeevan K.
Degulys, Andrius
Finelli, Carlo
Cluzeau, Thomas
Della Porta, Matteo Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study
Oliva, Esther Natalie
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Garcia-Manero, Guillermo
Santini, Valeria
Fenaux, Pierre
Shortt, Jake
Komrokji, Rami S.
Pelligra, Christopher
Guo, Shien
Lord-Bessen, Jennifer
Xiao, Hong
Yucel, Aylin
Miteva, Dimana
Rose, Shelonitda
Kreitz, Sandra
Sekeres, Mikkael A.
Zeidan, Amer M.
BLOOD, 2023, 142
[4] Reduction of Transfusion Burden (TB), Hemoglobin Increase, and Dose Titration in the COMMANDS Study of Luspatercept Versus Epoetin Alfa (EA) in Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Komrokji, Rami S.
Platzbecker, Uwe
Della Porta, Matteo
Santini, Valeria
Garcia-Manero, Guillermo
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Hughes, Christina
Valcarcel, David
Fenaux, Pierre
Shortt, Jake
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S358 - S359
[5] Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
Santini, Valeria
Zeidan, Amer M.
Platzbecker, Uwe
Komrokji, Rami S.
Garcia-Manero, Guillermo
Miteva, Dimana
Yucel, Aylin
Pozharskaya, Veronika
Rose, Shelonitda
Lai, Yinzhi
Giuseppi, Ana Carolina
Ferreiras, David Valcarcel
Fenaux, Pierre
Shortt, Jake
Porta, Matteo Giovanni Della
BLOOD, 2024, 144 : 1818 - 1820
[6] Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study
Platzbecker, U.
Della Porta, M. G.
Santini, V.
Zeidan, A. M.
Fenaux, P.
Komrokji, R. S.
Shortt, J.
Valcarcel, D.
Jonasova, A.
Dimicoli-Salazar, S.
Tiong, I. S.
Lin, C. -C.
Li, J.
Zhang, J.
Giuseppi, A. C.
Kreitz, S.
Pozharskaya, V.
Keeperman, K. L.
Rose, S.
Shetty, J. K.
Hayati, S.
Vodala, S.
Degulys, A.
Paolini, S.
Cluzeau, T.
Garcia-Manero, G.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 16 - 17
[7] Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Shetty, Jeevan K.
Hayati, Sheida
Vodala, Sadanand
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Della Porta, Matteo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S355 - S356
[8] Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion- dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Santini, Valeria
Zeidan, Amer M.
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Shetty, Jeevan K.
Hayati, Sheida
Vodala, Sadanand
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Fenaux, Pierre
Garcia-Manero, Guillermo
LANCET, 2023, 402 (10399): : 373 - 385
[9] Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial
Platzbecker, Uwe
Zhu, Yiming
Ha, Xianwei
Risueno, Alberto
Chan, Esther
Zhang, George
Dunshee, Diana R.
Acar, Melih
Shetty, Jeevan K.
Ito, Rodrigo
MacBeth, Kyle
Santini, Valeria
Garbowski, Maciej W.
Fenaux, Pierre
Schwickart, Martin
BLOOD, 2020, 136
[10] Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial
Zeidan, Amer M.
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Santini, Valeria
Garcia-Manero, Guillermo
Li, Jiahui
Kreitz, Sandra
Pozharskaya, Veronika
Rose, Shelonitda
Lai, Yinzhi
Valcarcel, David
Fenaux, Pierre
Shortt, Jake
Komrokji, Rami S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S387 - S388

← 1 2 3 4 5 →